Inducible PPARγ Expression in Lung Cancer

Lung cancer cells were cultured in RPMI 1640 (H2073, H3255, H2347, Calu6, and H1993) or DMEM media (H1299 and A549) supplemented with 5% FBS, 50 U/mL penicillin, and 50 U/mL streptomycin, at 37°C, 5% CO₂ atmosphere. Cells were periodically tested for mycoplasma contamination. HBEC stable cell lines with inducible PPARγ expression were generated as previously reported [15 (link)]. Particularly, HBEC cells containing wild-type PPARγ or sumoylation mutant PPARγ (K107, 395R), HBEC-PPARγWT and HBEC-PPARγSUMO, are two tumorigenic clones in which biotin ligase recognition peptide (BLRP)-tagged PPARγWT or PPARγSUMO are tightly regulated upon tetracycline treatment. HBEC cells were cultured in RPMI 1640 supplemented with 10% FBS, 50 U/mL penicillin and 50 U/mL streptomycin. PPARγ agonists (pioglitazone and troglitazone) were purchased from Santa Cruz, tetracycline was from Sigma.